LLY

Business Context and Reporting Period

Company: Eli Lilly & Co.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2005
Business Overview: Eli Lilly operates primarily in the pharmaceutical products segment, with a smaller animal health segment. The company markets products in neurosciences, endocrinology, oncology, and cardiovascular health.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss in Q2 2005: The company reported a net loss of $252.0 million in Q2 2005, a reversal from a net income of $656.9 million in Q2 2004. This was primarily driven by a $1.07 billion pre-tax charge for product liability matters related to Zyprexa litigation.
• Revenue Growth: Net sales increased 3% year-over-year for both the quarter and the six-month period. Growth was driven by Cymbalta, Alimta, Gemzar, and Forteo, partially offset by a 10% decline in Zyprexa sales and wholesaler destocking.
• Expense Increases: Research and development expenses rose 11% in Q2 2005 to $762.4 million, influenced by increased clinical trial costs and the adoption of SFAS 123(R) requiring stock option expensing.
• Accounting Changes: The adoption of SFAS 123(R) in 2005 resulted in the recognition of stock-based compensation expense, reducing net income by approximately $55.6 million in Q2 2005 compared to prior accounting methods.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• 2005 EPS Guidance: Management expects full-year 2005 earnings per share to be in the range of $1.90 to $1.96. This includes the $0.90 per share impact from the Q2 product liability charge and incremental equity compensation expenses.
• 2005 Sales Growth: Expected to grow 6% to 8% for the full year, with acceleration anticipated in the second half.
• Product Liability Settlement: In June 2005, the company entered an agreement in principle to settle the majority of U.S. Zyprexa product liability claims. This involves a $690 million fund for claimants plus $10 million for administration. The settlement is estimated to cover approximately 75% of identified claims.
• Debt Strategy: While debt was reduced by $1.84 billion in the first half of 2005, the company expects to incrementally increase debt by approximately $2 billion for the remainder of 2005 to fund the Zyprexa settlement and an IRS tax resolution.

Risks and Contingencies

• Zyprexa Litigation: Significant risks remain regarding the finalization of the settlement, potential additional claims, and ongoing patent challenges by generic manufacturers (Zenith, Reddy, Teva) which are currently on appeal.
• Government Investigations: The company is cooperating with civil investigations by the U.S. Attorney's office and state authorities regarding marketing practices for Zyprexa, Prozac, and Prozac Weekly. Outcomes could include fines or penalties.
• Insurance Recoveries: The company is litigating with certain insurance carriers regarding coverage for Zyprexa claims; the timing and amount of recoveries are uncertain.

Investor Verification Checklist

• Settlement Finalization: Verify the status of the final Zyprexa settlement agreement and whether the $700 million charge covers all anticipated liabilities.
• Insurance Recovery: Monitor the outcome of lawsuits filed against insurance carriers to determine the net cash impact of the litigation charges.
• Patent Appeals: Track the appeal of the district court ruling upholding the 2011 Zyprexa patent, as a loss could accelerate generic competition.
• Wholesaler Inventory: Assess the impact of wholesaler destocking on future sales trends, particularly for Zyprexa and Strattera.
• Debt Levels: Confirm the execution of the planned $2 billion debt increase in the second half of 2005 and its impact on interest expense.